Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daniel H. Deon is active.

Publication


Featured researches published by Daniel H. Deon.


Journal of General Virology | 2011

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization

Dike Qiu; Julie A. Lemm; Donald R. O’Boyle; Jin-Hua Sun; Peter T. Nower; Van N. Nguyen; Lawrence G. Hamann; Lawrence B. Snyder; Daniel H. Deon; Edward H. Ruediger; Nicholas A. Meanwell; Makonen Belema; Min Gao; Robert A. Fridell

Hepatitis C virus (HCV) non-structural protein 5A (NS5A) is a multi-functional protein that is expressed in basally phosphorylated (p56) and in hyperphosphorylated (p58) forms. NS5A phosphorylation has been implicated in regulating multiple aspects of HCV replication. We recently reported the identification of a class of compounds that potently inhibit HCV RNA replication by targeting NS5A. Although the precise mechanism of inhibition of these compounds is not well understood, one activity that has been described is their ability to block expression of the hyperphosphorylated form of NS5A. Here, we report that an NS5A inhibitor impaired hyperphosphorylation without affecting basal phosphorylation at the C-terminal region of NS5A. This inhibitor activity did not require NS5A domains II and III and was distinct from that of a cellular kinase inhibitor that also blocked NS5A hyperphosphorylation, results that are consistent with an inhibitor-binding site within the N-terminal region of NS5A. In addition, we observed that an NS5A inhibitor promoted the accumulation of an HCV polyprotein intermediate, suggesting that inhibitor binding to NS5A may occur prior to the completion of polyprotein processing. Finally, we observed that NS5A p56 and p58 separated into different membrane fractions during discontinuous sucrose gradient centrifugation, consistent with these NS5A phosphoforms performing distinct replication functions. The p58 localization pattern was disrupted by an NS5A inhibitor. Collectively, our results suggest that NS5A inhibitors probably impact several aspects of HCV expression and regulation. These findings may help to explain the exceptional potency of this class of HCV replication complex inhibitors.


Archive | 2003

Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides

Tao Wang; John F. Kadow; Nicholas A. Meanwell; Kap-Sun Yeung; Zhongxing Zhang; Zhiwei Yin; Zhilei Qiu; Daniel H. Deon; Clint A. James; Edward H. Ruediger; Carol Bachand


Archive | 2009

Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors

Carol Bachand; Makonen Belema; Daniel H. Deon; Andrew C. Good; Jason Goodrich; Clint A. James; Rico Lavoie; Omar D. Lopez; Alain Martel; Nicholas A. Meanwell; Van N. Nguyen; Jeffrey L. Romine; Edward H. Ruediger; Lawrence B. Snyder; R Laurent Denis; Fukang Yang; David R. Langley; Gan Wang; Lawrence G. Hamann


Archive | 2008

Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors

Carol Bachand; Makonen Belema; Daniel H. Deon; Andrew C. Good; Jason Goodrich; Clint A. James; Rico Lavoie; Omar D. Lopez; Alain Martel; Nicholas A. Meanwell; Van N. Nguyen; Jeffrey L. Romine; Edward H. Ruediger; Lawrence B. Snyder; R Laurent Denis; Fukang Yang; David R. Langley; Gan Wang; Lawrence G. Hamann


Archive | 2009

Heterocyclic derivatives as hepatitis c virus inhibitors

Carol Bachand; Belema Makonen; Daniel H. Deon; Andrew C. Good; Jason Goodrich; Clint A. James; Rico Lavoie; Omar D. Lopez; Alain Martel; Nicholas A. Meanwell; Van N. Nguyen; Jeffrey L. Romine; Edward H. Ruediger; Lawrence B. Snyder; R Laurent Denis; Fukang Yang; David R. Langley; Gan Wang; Lawrence G. Hamann


Archive | 2013

Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation

Michael R Lawrence; Michael M. Miller; Dietmar Seiffert; Shoshana Posy; Pancras C. Wong; Jacques Banville; Edward H. Ruediger; Daniel H. Deon; Alain Martel; François Tremblay; Julia Guy; Jean-Francois Lavallee; Marc Gagnon


Archive | 2005

Tetrahydrocarboline antiviral agents

Edward H. Ruediger; Daniel H. Deon; John F. Kadow


Archive | 2007

4-Squarylpiperazine derivatives as antiviral agents

Carol Bachand; Daniel H. Deon; Edward H. Ruediger


Archive | 2017

derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta

Alain Martel; Daniel H. Deon; Dietmar A. Seiffert; Edward H. Ruediger; François Tremblay; Jacques Banville; Jean François Lavallee; Julia Guy; Marc Gagnon; Michael M. Miller; Michael R Lawrence; Pancras C. Wong; Shoshana Posy


Archive | 2017

derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta

Brad D. Maxwell; Daniel H. Deon; Edward H. Ruediger; Eldon Scott Priestley; Jacques Banville; Julia Guy; Laurence Dube; Marc Gagnon; Michael M. Miller; Michael R Lawrence; Pancras C. Wong; Roger Remillard; Shoshana Posy

Collaboration


Dive into the Daniel H. Deon's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge